The American Academy of Pediatrics (AAP) has issued its recommendations for the 2020-2021 influenza season.
The American Academy of Pediatrics (AAP) has issued its immunization and treatment recommendations for the 2020-2021 influenza season.1
Although COVID-19 may be the disease at the forefront of most people’s mind, the annual influenza season is due to start in the near future. How it will look when running concurrently with a pandemic is unknown at this point, but the disease could further tax the health care system with the hospitalizations and deaths caused by the illness annually.
The AAP continues its recommendation of routine influenza immunizations for every child who has no medical contraindications, starting at age 6 months. A child should be given any licensed, recommended, age-appropriate vaccine that is available without regard to product or formulation. For children who either have a suspected or confirmed case of influenza and is hospitalized, has severe disease, or an underlying condition that could increase the risk of complications, antiviral treatment should be administered. For children who are not at high risk of complications from influenza, antiviral medication may be used if it can be started within 48 hours of the disease’s onset or if the child has someone in the household who is either aged younger than 6 months or who has a condition that predisposes them to complications from influenza.
To continue reading this article, visit Contemporary Pediatrics.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.